Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral...

Area of Science:

• Cardiology
• Clinical Risk Stratification
• Biomarker Research

Background:

• The ABC (Age, Biomarkers, Clinical History) scores demonstrate superior performance in predicting adverse events for atrial fibrillation (AF) patients on oral anticoagulation.
• Validation of these ABC-AF scores in AF patients not receiving oral anticoagulation is crucial for broader clinical application.

Purpose of the Study:

• To validate and recalibrate the ABC-AF scores for predicting stroke, major bleeding, and death in atrial fibrillation patients treated with aspirin or aspirin and clopidogrel.
• To assess the performance of ABC-AF scores compared to traditional risk scores in this patient population.

Main Methods:

• Plasma levels of established ABC biomarkers (NT-proBNP, troponin-T, GDF-15) were measured in AF patients from two large clinical trials.
• The previously developed ABC-AF scores were applied to cohorts receiving aspirin (n=3195) and dual antiplatelet therapy (n=1110).
• Calibration and discrimination (c-index) were assessed, and Cox regression models were used for recalibration.

Main Results:

• The ABC-AF-stroke score achieved a c-index of 0.70, ABC-AF-bleeding 0.73 overall, and ABC-AF-death 0.78 overall, outperforming guideline-recommended scores.
• Recalibration was necessary as the original scores underestimated stroke risk and overestimated bleeding risk in this cohort.
• The recalibrated scores provide precise risk estimation for patients not on oral anticoagulation.

Conclusions:

• Biomarker-based ABC-AF scores demonstrate superior discrimination for adverse events in AF patients not on oral anticoagulation.
• Recalibration enables precise risk estimation, enhancing the utility of ABC-AF scores for clinical decision support.
• These validated and recalibrated scores improve the management of individual AF patients.